Angina News and Research

RSS

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.

Improvement of postoperative care decreases myocardial ischemia and major cardiac events

A study published in the October 2010 issue of Anesthesiology is among the first to show that the quality of immediate postoperative care of orthopedic surgery patients has important effects on patients' long-term cardiac outcomes.

25 Aug 2010

Sleep deprivation and chronic disease

Sleep experts believe that sleep deprivation and inadequate sleep is becoming frightfully common and it can be bad for health in more ways than one. According to Harvard School of Medicine's Healthy Sleep site there is a real link between chronic diseases like diabetes, heart disease and depression and chronic lack of sleep.

24 Aug 2010

Dilation of blood vessels restores muscle synthesis in elderly

University of Texas Medical Branch at Galveston researchers believe they've found a way to use widely available blood pressure drugs to fight the muscular weakness that normally accompanies aging.

21 Aug 2010

Neovasc revenue increases 60% for second quarter 2010

Neovasc Inc., today announced financial results for the three and six months ended June 30, 2010. "In this most recent quarter Neovasc continued to demonstrate robust year-over-year revenue growth from sales of our biological tissue and consulting services businesses," said Alexei Marko, chief executive officer of Neovasc.

19 Aug 2010

PLC Systems second-quarter total revenues decrease to $1,019,000

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three- and six month periods ended June 30, 2010.

16 Aug 2010

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Cardiogenesis second-quarter 2010 revenue increases 9% to $2.43 million

Cardiogenesis Corporation, a leading developer of surgical products used to treat cardiac patients suffering from severe angina, today reported financial results for its second quarter and first half ended June 30, 2010.

5 Aug 2010

Abnormal sleep duration adversely affects cardiovascular health

A study in the Aug. 1 issue of the journal Sleep suggests that regularly sleeping for more or less than seven hours per day is associated with an increased risk of cardiovascular disease.

2 Aug 2010

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

AstraZeneca today announced that the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes.

29 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.

21 Jul 2010

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.

15 Jul 2010

Women with serious form of angina have higher risk of developing CAD: Researchers

Women who have the most serious form of angina are three times as likely to develop severe coronary artery disease as men with the same condition, according to the July issue of the Journal of Internal Medicine.

9 Jul 2010

Older men with high testosterone levels more likely to have heart attacks

A large U.S. multicenter study shows that older men with higher testosterone levels are more likely to have a heart attack or other cardiovascular disease in the future. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Bayer signs agreement to supply Adalat XL product to Teva Canada

Bayer Inc. and Teva Canada Limited today announced they have entered an agreement regarding Bayer's Adalat XL (nifedipine) 20, 30 and 60 mg product. Effective immediately, Bayer Inc. will supply Adalat XL exclusively to Teva Canada Limited and Teva Canada Limited will become the sole distributor in Canada of brand name Adalat XL product.

28 Jun 2010

Mylan granted final FDA approval for Procardia XL Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Nifedipine Extended-release Tablets USP, 30 mg, 60 mg and 90 mg, the generic version of Pfizer's Procardia XL® Tablets, a treatment for angina and/or hypertension.

25 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

24 Jun 2010

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced patient enrollment has commenced in the Company's pivotal VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks) Phase 3 clinical study of varespladib (A-002).

23 Jun 2010

Angina News and Research

Further Reading

Improvement of postoperative care decreases myocardial ischemia and major cardiac events

Sleep deprivation and chronic disease

Dilation of blood vessels restores muscle synthesis in elderly

Neovasc revenue increases 60% for second quarter 2010

PLC Systems second-quarter total revenues decrease to $1,019,000

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Cardiogenesis second-quarter 2010 revenue increases 9% to $2.43 million

Abnormal sleep duration adversely affects cardiovascular health

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

Women with serious form of angina have higher risk of developing CAD: Researchers

Older men with high testosterone levels more likely to have heart attacks

Bayer signs agreement to supply Adalat XL product to Teva Canada

Mylan granted final FDA approval for Procardia XL Tablets

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Anthera commences enrollment in pivotal VISTA-16 Phase 3 clinical study of varespladib

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News